Search hospitals > Arizona > Scottsdale
HonorHealth Research Institute
Claim this profileScottsdale, Arizona 85258
Global Leader in Solid Tumors
Global Leader in Pancreatic Cancer
Conducts research for Uterine Tumors
Conducts research for Skin Cancer
Conducts research for Stomach Cancer
152 reported clinical trials
14 medical researchers
Summary
HonorHealth Research Institute is a medical facility located in Scottsdale, Arizona. This center is recognized for care of Solid Tumors, Pancreatic Cancer, Uterine Tumors, Skin Cancer, Stomach Cancer and other specialties. HonorHealth Research Institute is involved with conducting 152 clinical trials across 230 conditions. There are 14 research doctors associated with this hospital, such as Vincent Chung, MD, Michael S Gordon, MD, Sunil Sharma, and Erkut Borazanci, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
metastatic
2Pancreatic Cancer
Global LeaderStage IV
Stage III
metastatic
Top PIs
Vincent Chung, MDCity of Hope Medical Center2 years of reported clinical research
Expert in Pancreatic Cancer
Expert in Stomach Cancer
21 reported clinical trials
33 drugs studied
Michael S Gordon, MDHonor Health Research Institute2 years of reported clinical research
Studies Uterine Tumors
Studies Solid Tumors
18 reported clinical trials
26 drugs studied
Sunil SharmaHonorHealth Research Institute1 year of reported clinical research
Studies Skin Cancer
Studies Solid Tumors
16 reported clinical trials
34 drugs studied
Erkut Borazanci, MDHonor Health Research Institute2 years of reported clinical research
Expert in Pancreatic Cancer
Studies Uterine Tumors
16 reported clinical trials
27 drugs studied
Clinical Trials running at HonorHealth Research Institute
Solid Tumors
Uterine Tumors
Breast Cancer
Skin Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Stomach Cancer
Pancreatic Cancer
Lung Cancer
Cancer
Dabrafenib + Trametinib Access
for Cancer
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Recruiting3 awards Phase 42 criteria
GIM-531
for Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Recruiting1 award Phase 1 & 24 criteria
KB707
for Lung Cancer
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1/2, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced solid tumor malignancies affecting the lungs who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy, as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Keytruda, with or without chemotherapy, to subjects with advanced NSCLC. The study will include a dose escalation portion for single agent KB707 using a standard 3+3 design followed by a dose expansion portion to further evaluate single agent KB707 at a dose determined by preliminary data in the dose escalation phase. Subjects in the dose escalation (Cohorts 1 and 2) and dose expansion (Cohort 4) will receive KB707 via nebulization weekly for three weeks, then every three weeks. The dose escalation portion of the study has now closed, and the Cohort 2 dose was selected for evaluation in dose expansion. Dose expansion Cohorts 5 and 6 will evaluate subjects with advanced non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 will receive inhaled KB707 per treatment day once every 2 weeks (q2w), delivered in combination with Keytruda (once every 6 weeks). All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.
Recruiting1 award Phase 1 & 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at HonorHealth Research Institute?
HonorHealth Research Institute is a medical facility located in Scottsdale, Arizona. This center is recognized for care of Solid Tumors, Pancreatic Cancer, Uterine Tumors, Skin Cancer, Stomach Cancer and other specialties. HonorHealth Research Institute is involved with conducting 152 clinical trials across 230 conditions. There are 14 research doctors associated with this hospital, such as Vincent Chung, MD, Michael S Gordon, MD, Sunil Sharma, and Erkut Borazanci, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.